Email this article Tartratrezistentnaya kislaya fosfataza osteoklastov (TRAP-5b) v syvorotke krovi u patsientov s pervichnymi opukholyami kostey
- Authors: Derzhavin VA1, Sergeeva NS1, Teplyakov VV1, Marshutina NV1, Solokhina MP1, Machak GN1
-
Affiliations:
- Issue: Vol 14, No 1 (2009)
- Pages: 14-16
- Section: Articles
- URL: https://rjonco.com/1028-9984/article/view/39780
- DOI: https://doi.org/10.17816/onco39780
- ID: 39780
Cite item
Full Text
Abstract
The purpose of the ivestigation was to study whether osteoclast-derived serum tartrate-resistant acid (TRAP-5b) can be used as a tumor marker in the presence of primary bone neoplasms. The study included 34 patients with primary bone malignancies (Group 1), 35 with benign tumors and traumatic bone fractures (Group 2), and 38 apparently healthy donors (Group 3). All the groups were age-matched and gender-matched. TRAP-5b levels were studied by enzyme immunoassay. The low (less than 3 U/l) serum concentration of TRAP-5b was found in 39, 31, and 3% in Groups 1, 2, and 3, respectively. The TRAP-5b levels exceeding 6.0 U/l were seen in 1 examinee from Group 3, in 1 patient from Group 2 and in 35% of Group 1 patients. The highest concentrations (7.74±0.73 U/l) of TRAP-5b were detected in patients with osteolytic bone destruction, the least (4.48±0.92 U/l) in mixed one.
References
- Анисеня И. И. // Опухоли костей (клиника, диагностика, лечение). - Томск, 1990. - С. 159-191.
- Ермакова И. П. // Лаборатория. - 2001. - № 3. - С. 3-5.
- Ефанов В. В., Сергеева Н. С., Пак Д. Д. и др. // Рос. онкол. журн. - 2008. - № 6. - С. 12-15.
- Любимова Н. В., Козарская Г. В., Морозов А. П. // Материалы 19-го ежегодного конгресса Европейского общества по изучению костей и мягких тканей: Вестн. РОНЦ. - 2006. - № 1, прил. 1. - С. 29.
- Махсон Н. Е., Махсон А. Н. Адекватная хирургия при опухолях плечевого и тазового пояса. Реальное время. - М., 1998. - С. 5-6.
- Некачалов В. В. Патология костей и суставов: Руководство. - СПб., 2000. - С. 288.
- Слонимская Е. М. // Опухоли костей (клиника, диагностика, лечение). - Томск, 1990. - С. 211-224.
- Berenson J. R., Rosen L. S. et al. // Clin. Cancer Res. - 2001. - Vol. 7. - P. 478-485.
- Capeller B., Caffier H. et al. // Anticancer Res. - 2003. - Vol. 23. - P. 5.
- Halleen J. M., Alatalo S. L. et al. // Clin. Chem. - 2001. - Vol. 47. - P. 597-600.
- Horowitz M. E., Malawer M. M., Woo S. Y. et al. // Principles and practice of pediatric oncology / Eds P. A. Pizzo, D. G. Poplack. - 3-rd Ed. - Philadelphia, 1997. - P. 831.
- Izumi M., Nakanishi Y. et al. // Cancer. - 2001. - Vol. 91. - P. 1487-1493.
- Sugarbaker P., Malawer M. Musculoskeletal Cancer Surgery. - 2001. - P. 4.
- Vaananen H. K., Zhao H., Mulari M. A., Halleen J. M. // J. Cell Sci. - 2000. - Vol. 113. - P. 81.
Supplementary files
